Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biorestorative Therapies Inc (NQ: BRTX )

1.600 -0.090 (-5.32%)
Streaming Delayed Price Updated: 3:59 PM EDT, Sep 21, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 24,604
Open 1.700
Bid (Size) 1.680 (1)
Ask (Size) 1.750 (4)
Prev. Close 1.690
Today's Range 1.510 - 1.710
52wk Range 1.410 - 7.130
Shares Outstanding 4,667,641
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Roth MKM Analyst Projects An Impressive Price Target of $15 Over The Next 12 Months For BioRestorative Therapies (NASDAQ: BRTX), Says “Low Valuation Undeserved”
Via ACCESSWIRE
Roth MKM Analyst Projects An Impressive Price Target Of $15 Over The Next 12 Months For BioRestorative Therapies (NASDAQ: BRTX), Says "Low Valuation Undeserved"
BioRestorative Therapies Inc. (NASDAQ: BRTX) (“BioRestorative”) is a clinical-stage biotech company that is developing cell-based therapies to treat chronic lumbar disc disease and metabolic conditions... 
Via Benzinga

Performance

YTD
-41.17%
-41.17%
1 Month
-35.74%
-35.74%
3 Month
-72.34%
-72.34%
6 Month
-50.61%
-50.61%
1 Year
-49.20%
-49.20%

More News

Read More
EXCLUSIVE: Stem Cell Focused BioRestorative Ventures Into $63B Aesthetics Market Via Supply Agreement With Evolutionary Biologics
Via Benzinga
Topics Supply Chain
Exposures Supply Chain
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
BioRestorative Therapies And 3 Other Stocks Under $3 Insiders Are Buying
Via Benzinga
Topics Stocks
Exposures US Equities
As America Grapples With A Deadly Opioid Epidemic, BioRestorative Therapies Is Looking To Treat Chronic Pain Without The Need For Class-A Drugs
Via ACCESSWIRE
As America Grapples With A Deadly Opioid Epidemic, BioRestorative Therapies Is Looking To Treat Chronic Pain Without The Need For Class-A Drugs
Via Benzinga
BioRestorative Therapies Gains Additional Investor Confidence As Insider Dale Broadrick, CEO Lance Alstodt Purchase Thousands of Shares
Via ACCESSWIRE
BioRestorative Therapies Gains Additional Investor Confidence As Insider Dale Broadrick, CEO Lance Alstodt Purchase Thousands of Shares
Via Benzinga
Chronic Pain Specialist Speaks At Panel On Stem Cell-Based Therapies And The Need For Spinal Care Reform - Insights From The Discussion
Via ACCESSWIRE
Over $4M Bet On Yellow Corp? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying
Via Benzinga
Chronic Pain Specialist Speaks At Panel On Stem Cell-Based Therapies And The Need For Spinal Care Reform – Insights From The Discussion
Via Benzinga
$5.7M Bet On This Tech Stock? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
Why Metropolitan Bank Holding Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
BioRestorative Therapies (NASDAQ:BRTX) Receives Landmark License From New York State
Via ACCESSWIRE
BioRestorative Therapies (NASDAQ: BRTX) Receives Landmark License From New York State
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Why Siyata Mobile Shares Are Trading Lower By 21%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Why BioRestorative Therapies (BRTX) Stock Is Getting Hammered
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
BioRestorative Therapies' Drug Candidate BRTX-100 Passes Safety Test With Flying Colors, Moves Ahead With Phase 2 And Looks To Expand Pipeline Opportunities
Via ACCESSWIRE
BioRestorative Therapies' Drug Candidate BRTX-100 Passes Safety Test With Flying Colors, Moves Ahead With Phase 2 And Looks To Expand Pipeline Opportunities
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.